Pioglitazone: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
* Marketed By: Takeda Pharmaceuticals<br /> | * Marketed By: Takeda Pharmaceuticals<br /> | ||
* Major Indication: Hypoglycemia & Type 2 [[Diabetes]]<br /> | * Major Indication: Hypoglycemia & Type 2 [[Diabetes]]<br /> | ||
* Drug Class: [[PPAR|PPAR-γ]] | * Drug Class: [[PPAR|PPAR-γ]] Agonist - Thiazolidinedione (Glitazones) | ||
* Date of FDA Approval (Patent Expiration): 1999 (2011)<br /> | * Date of FDA Approval (Patent Expiration): 1999 (2011)<br /> | ||
* 2009 Sales: $2.4 Billion <ref>http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=ACTOS</ref> | * 2009 Sales: $2.4 Billion <ref>http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=ACTOS</ref> | ||
